MX2020001358A - Celulas t que redirigen el receptor del antigeno quimerico especifico cd123 y metodos de su uso. - Google Patents
Celulas t que redirigen el receptor del antigeno quimerico especifico cd123 y metodos de su uso.Info
- Publication number
- MX2020001358A MX2020001358A MX2020001358A MX2020001358A MX2020001358A MX 2020001358 A MX2020001358 A MX 2020001358A MX 2020001358 A MX2020001358 A MX 2020001358A MX 2020001358 A MX2020001358 A MX 2020001358A MX 2020001358 A MX2020001358 A MX 2020001358A
- Authority
- MX
- Mexico
- Prior art keywords
- cells
- chimeric antigen
- aml
- substitution
- cd123car
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 6
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title abstract 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 4
- 238000006467 substitution reaction Methods 0.000 abstract 3
- 108091008874 T cell receptors Proteins 0.000 abstract 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 230000011664 signaling Effects 0.000 abstract 2
- 241000699670 Mus sp. Species 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000000139 costimulatory effect Effects 0.000 abstract 1
- 230000003111 delayed effect Effects 0.000 abstract 1
- 239000012636 effector Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000013610 patient sample Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464419—Receptors for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/17—Hinge-spacer domain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se desarrolló una familia de receptores de antígeno quimérico (CARs) que contiene scFv específico CD123 para dirigir diferentes epítopos en CD123. En algunas modalidades, tal gen del receptor de antígeno quimérico CD123 (CD123CAR) incluye una región scFv anti-CD123 fusionada en el marco a una región de bisagra IgG4 modificada que comprende una sustitución S228P, una sustitución L235E, y opcionalmente una sustitución N297Q; un dominio de señalización coestimulante; y un dominio de señalización de cadena zeta del receptor de célula T (TCR). Cuando se expresan en células T de donador saludable (CD4/CD8), los CD123CARs redirigen la especificidad de la célula T y median la actividad efectora potente contra las líneas de célula CD123+ así como muestras de paciente AML primarias. Además, las células T obtenidas de pacientes con AML activo, pueden modificarse para expresar genes CD123CAR y son capaces de lisar blastos AML autólogos in vitro. Finalmente, una dosis sencilla de 5.0 x 106 células T CAR123 resulta en un progreso leucémico significativamente retardado en ratones. Estos resultados sugieren que las células T transducidas con CD123CAR pueden usarse como una inmunoterapia para el tratamiento de AML de alto riesgo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/844,048 US9657105B2 (en) | 2013-03-15 | 2013-03-15 | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020001358A true MX2020001358A (es) | 2020-08-20 |
Family
ID=51527938
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015013195A MX2015013195A (es) | 2013-03-15 | 2014-03-14 | Celulas t que redirigen el receptor del antigeno quimerico especifico cd123 y metodos de su uso. |
MX2020001358A MX2020001358A (es) | 2013-03-15 | 2015-09-15 | Celulas t que redirigen el receptor del antigeno quimerico especifico cd123 y metodos de su uso. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015013195A MX2015013195A (es) | 2013-03-15 | 2014-03-14 | Celulas t que redirigen el receptor del antigeno quimerico especifico cd123 y metodos de su uso. |
Country Status (16)
Country | Link |
---|---|
US (3) | US9657105B2 (es) |
EP (2) | EP3626247B1 (es) |
JP (4) | JP6588004B2 (es) |
KR (4) | KR102416258B1 (es) |
CN (2) | CN105392887B (es) |
AU (3) | AU2014228911A1 (es) |
BR (1) | BR112015023701B1 (es) |
CA (1) | CA2907216C (es) |
DK (1) | DK2968415T3 (es) |
ES (1) | ES2747099T3 (es) |
HK (1) | HK1222677A1 (es) |
IL (4) | IL298332A (es) |
MX (2) | MX2015013195A (es) |
NZ (1) | NZ712351A (es) |
RU (1) | RU2711114C2 (es) |
WO (1) | WO2014144622A2 (es) |
Families Citing this family (125)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2814962T3 (es) | 2013-02-20 | 2021-03-29 | Novartis Ag | Fijación eficaz como objetivo de la leucemia humana primaria utilizando células T modificadas con receptor de antígeno quimérico anti-CD123 |
US9657105B2 (en) | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
TWI654206B (zh) | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗-cd19嵌合抗原受體治療癌症 |
DK2997134T3 (da) | 2013-05-14 | 2020-09-28 | Univ Texas | Human anvendelse af genmanipulerede kimære antigenreceptor-(car)-t-celler |
CA2913052A1 (en) | 2013-05-24 | 2014-11-27 | Board Of Regents, The University Of Texas System | Chimeric antigen receptor-targeting monoclonal antibodies |
JP6585041B2 (ja) | 2013-07-18 | 2019-10-02 | ベイラー カレッジ オブ メディスンBaylor College Of Medicine | 免疫細胞の能力を増強する方法 |
JP6560235B2 (ja) * | 2014-01-13 | 2019-08-14 | シティ・オブ・ホープCity of Hope | Fcスペーサー領域に変異を有するキメラ抗原受容体(CAR)及びそれらの使用方法 |
US10189908B2 (en) | 2014-02-05 | 2019-01-29 | The University Of Chicago | Chimeric antigen receptors recognizing cancer-specific TN glycopeptide variants |
RU2727290C2 (ru) * | 2014-03-19 | 2020-07-21 | Селлектис | Cd123-специфические химерные антигенные рецепторы для иммунотерапии рака |
KR20240042250A (ko) * | 2014-04-07 | 2024-04-01 | 노파르티스 아게 | 항-cd19 키메라 항원 수용체를 사용한 암의 치료 |
US9212225B1 (en) | 2014-07-01 | 2015-12-15 | Amphivena Therapeutics, Inc. | Bispecific CD33 and CD3 binding proteins |
RU2741120C2 (ru) | 2014-07-21 | 2021-01-22 | Новартис Аг | Лечение рака с использованием химерного антигенного рецептора cll-1 |
MX2017001011A (es) | 2014-07-21 | 2018-05-28 | Novartis Ag | Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma. |
US20170209492A1 (en) * | 2014-07-31 | 2017-07-27 | Novartis Ag | Subset-optimized chimeric antigen receptor-containing t-cells |
SG11201700770PA (en) | 2014-08-19 | 2017-03-30 | Novartis Ag | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment |
EP2990416B1 (en) | 2014-08-29 | 2018-06-20 | GEMoaB Monoclonals GmbH | Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
WO2016044811A1 (en) * | 2014-09-19 | 2016-03-24 | City Of Hope | COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Rα2 |
EP3536707A1 (en) * | 2014-11-05 | 2019-09-11 | Board of Regents, The University of Texas System | Gene modified immune effector cells and engineered cells for expansion of immune effector cells |
US20180334490A1 (en) | 2014-12-03 | 2018-11-22 | Qilong H. Wu | Methods for b cell preconditioning in car therapy |
WO2016094783A1 (en) | 2014-12-12 | 2016-06-16 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scaav |
PE20171764A1 (es) | 2015-01-23 | 2017-12-21 | Sanofi Sa | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123 |
CN107683289B (zh) | 2015-01-26 | 2021-08-06 | 芝加哥大学 | IL13Rα2结合剂和其在癌症治疗中的用途 |
WO2016123143A1 (en) | 2015-01-26 | 2016-08-04 | The University Of Chicago | CAR T-CELLS RECOGNIZING CANCER-SPECIFIC IL 13Rα2 |
EP3250606B1 (en) | 2015-01-26 | 2020-11-25 | Cellectis | Anti-cll1 specific single-chain chimeric antigen receptors (sccars) for cancer immunotherapy |
US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
IL284985B2 (en) | 2015-02-18 | 2023-03-01 | Enlivex Therapeutics R& D Ltd | Combined immunotherapy and cytokine control therapy for cancer treatment |
US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
KR20180012747A (ko) * | 2015-04-06 | 2018-02-06 | 서브도메인, 엘엘씨 | 드 노보 결합 도메인 함유 폴리펩티드 및 그의 용도 |
US10100118B2 (en) * | 2015-04-08 | 2018-10-16 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind CD123 |
MX2017012939A (es) | 2015-04-08 | 2018-05-22 | Novartis Ag | Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19. |
CN107708811B (zh) | 2015-04-21 | 2021-04-30 | 恩立夫克治疗有限责任公司 | 治疗性汇集的血液凋亡细胞制剂与其用途 |
WO2016180467A1 (en) * | 2015-05-11 | 2016-11-17 | Biontech Cell & Gene Therapies Gmbh | Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination |
MX2017015380A (es) | 2015-05-29 | 2018-03-28 | Amphivena Therapeutics Inc | Metodos para utilizar proteinas de enlace biespecificas cd3 y cd33. |
HUE054201T2 (hu) | 2015-06-19 | 2021-08-30 | Endres Stefan Prof Dr | PD-1-CD28 fúziós fehérjék és gyógyászatban való alkalmazásuk |
JP2018518972A (ja) | 2015-06-26 | 2018-07-19 | ユニバーシティ オブ サザン カリフォルニア | 腫瘍特異的活性化のためのマスキングキメラ抗原受容体t細胞 |
JP6751493B2 (ja) * | 2015-08-05 | 2020-09-09 | セルレブメド インコーポレーテッド | キメラ抗原受容体及びキメラ抗原受容体が発現されたt細胞 |
EP3569244A1 (en) * | 2015-09-23 | 2019-11-20 | CytoImmune Therapeutics, LLC | Flt3 directed car cells for immunotherapy |
KR20180056770A (ko) * | 2015-10-06 | 2018-05-29 | 시티 오브 호프 | Psca로 표적화된 키메라 항원 수용체 |
CN108290939B (zh) | 2015-10-16 | 2023-01-13 | 纽约市哥伦比亚大学理事会 | 用于抑制谱系特异性抗原的组合物和方法 |
AU2016336868B2 (en) | 2015-10-16 | 2022-04-14 | Ludwig-Maximilians-Universität München | CXCR6-transduced T cells for targeted tumor therapy |
EP3842450A1 (en) | 2015-10-23 | 2021-06-30 | Eureka Therapeutics, Inc. | Antibody/t-cell receptor chimeric constructs and uses thereof |
WO2017075147A1 (en) | 2015-10-27 | 2017-05-04 | Board Of Regents, The University Of Texas System | Chimeric antigen receptor molecules and uses thereof |
BR112018009129A2 (pt) * | 2015-11-04 | 2019-02-26 | J. PRICEMAN Saul | receptores de antígeno quimérico que visam her2 |
JP7184645B2 (ja) * | 2015-12-03 | 2022-12-06 | ジュノー セラピューティクス インコーポレイテッド | 修飾キメラ受容体ならびに関連する組成物および方法 |
US11052111B2 (en) | 2015-12-08 | 2021-07-06 | Chimera Bioengineering, Inc. | Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses |
ES2944597T3 (es) | 2015-12-30 | 2023-06-22 | Novartis Ag | Terapias con células efectoras inmunitarias de eficacia mejorada |
JP6884155B2 (ja) | 2016-02-18 | 2021-06-09 | エンリヴェックス セラピューティクス リミテッド | 癌治療のための併用免疫療法及びサイトカイン制御療法 |
WO2017149515A1 (en) | 2016-03-04 | 2017-09-08 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
US11549099B2 (en) | 2016-03-23 | 2023-01-10 | Novartis Ag | Cell secreted minibodies and uses thereof |
AU2017244108B2 (en) * | 2016-03-29 | 2021-03-18 | University Of Southern California | Chimeric antigen receptors targeting cancer |
SG11201809041TA (en) | 2016-04-15 | 2018-11-29 | Novartis Ag | Compositions and methods for selective protein expression |
WO2017192536A1 (en) | 2016-05-02 | 2017-11-09 | University Of Kansas | Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy |
MX2018015414A (es) | 2016-06-30 | 2019-08-01 | Hoffmann La Roche | Terapia de célula t adoptiva mejorada. |
EP3490590A2 (en) | 2016-08-01 | 2019-06-05 | Novartis AG | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule |
CN107793481A (zh) * | 2016-08-31 | 2018-03-13 | 南京传奇生物科技有限公司 | 一种靶向人cd123的嵌合受体配体及其应用 |
CN107840889A (zh) * | 2016-09-19 | 2018-03-27 | 上海吉倍生物技术有限公司 | 高亲和力的抗cd123抗体及其应用 |
US10995152B2 (en) | 2016-10-26 | 2021-05-04 | The Board Of Trustees Of The Leland Stanford Junior University | Modified immunoglobulin hinge regions to reduce hemagglutination |
JP7222888B2 (ja) * | 2016-11-16 | 2023-02-15 | アブリンクス エン.ヴェー. | Cd123及びtcrアルファ/ベータに結合することが可能なt細胞動員ポリペプチド |
WO2018102761A1 (en) | 2016-12-02 | 2018-06-07 | City Of Hope | Methods for manufacturing and expanding t cells expressing chimeric antigen receptors and other receptors |
US11535662B2 (en) | 2017-01-26 | 2022-12-27 | Novartis Ag | CD28 compositions and methods for chimeric antigen receptor therapy |
US11649288B2 (en) | 2017-02-07 | 2023-05-16 | Seattle Children's Hospital | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
WO2018176159A1 (en) * | 2017-03-31 | 2018-10-04 | Zymeworks Inc. | Tumor antigen presentation inducer constructs and uses thereof |
US11344578B2 (en) | 2017-04-19 | 2022-05-31 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
CA3059755A1 (en) | 2017-04-26 | 2018-11-01 | Eureka Therapeutics, Inc. | Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof |
TWI832818B (zh) * | 2017-07-07 | 2024-02-21 | 南韓商韓美藥品股份有限公司 | 新穎的治療性酵素融合蛋白及其用途 |
EP3684408A1 (en) | 2017-09-19 | 2020-07-29 | Massachusetts Institute of Technology | Compositions for chimeric antigen receptor t cell therapy and uses thereof |
CN111629749A (zh) | 2017-10-18 | 2020-09-04 | 诺华股份有限公司 | 用于选择性蛋白质降解的组合物和方法 |
CN107759700A (zh) * | 2017-10-18 | 2018-03-06 | 银丰生物工程集团有限公司 | 靶向cd19抗原的转基因t细胞及其制备方法与应用 |
KR20200069358A (ko) * | 2017-10-25 | 2020-06-16 | 노파르티스 아게 | 키메라 항원 수용체 발현 세포의 제조 방법 |
CN111601823A (zh) * | 2017-11-07 | 2020-08-28 | 德克萨斯大学体系董事会 | 用car-t或car-nk细胞在癌症治疗中靶向lilrb4 |
US11464803B2 (en) | 2017-11-14 | 2022-10-11 | Arcellx, Inc. | D-domain containing polypeptides and uses thereof |
CA3082410A1 (en) | 2017-11-14 | 2019-05-23 | Arcellx, Inc. | Multifunctional immune cell therapies |
KR20200096769A (ko) | 2017-11-14 | 2020-08-13 | 아르셀엑스, 인크. | D-도메인 함유 폴리펩타이드 및 이의 용도 |
JP2021503885A (ja) | 2017-11-22 | 2021-02-15 | アイオバンス バイオセラピューティクス,インコーポレイテッド | 末梢血からの末梢血リンパ球(pbl)の拡大培養 |
GB201719646D0 (en) | 2017-11-27 | 2018-01-10 | Bivictrix Therapeutics Ltd | Therapy |
CN112292138A (zh) | 2018-01-22 | 2021-01-29 | 西雅图儿童医院(Dba西雅图儿童研究所) | Car t细胞的使用方法 |
CN108276495B (zh) * | 2018-01-24 | 2022-03-18 | 博生吉医药科技(苏州)有限公司 | 靶向csf1r嵌合抗原受体修饰的nk92mi细胞和t细胞及其制法和应用 |
EP3765514A1 (en) | 2018-03-14 | 2021-01-20 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Anti-cd33 chimeric antigen receptors and their uses |
EP3773631A4 (en) * | 2018-04-06 | 2022-02-09 | Mustang Bio, Inc. | MANUFACTURING PROCESSES FOR CELL-BASED THERAPEUTIC COMPOSITIONS |
US20210047405A1 (en) | 2018-04-27 | 2021-02-18 | Novartis Ag | Car t cell therapies with enhanced efficacy |
WO2019213282A1 (en) | 2018-05-01 | 2019-11-07 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
EP3801769A1 (en) | 2018-05-25 | 2021-04-14 | Novartis AG | Combination therapy with chimeric antigen receptor (car) therapies |
EP3802825A1 (en) | 2018-06-08 | 2021-04-14 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
CN112203725A (zh) | 2018-06-13 | 2021-01-08 | 诺华股份有限公司 | Bcma嵌合抗原受体及其用途 |
WO2020007593A1 (en) * | 2018-07-02 | 2020-01-09 | Cellectis | Chimeric antigen receptors (car)-expressing cells and combination treatment for immunotherapy of patients with relapse refractory adverse genetic risk aml |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
AU2019301147A1 (en) * | 2018-07-10 | 2021-01-21 | Precigen, Inc. | ROR-1 specific chimeric antigen receptors and uses thereof |
SG11202100935TA (en) | 2018-09-28 | 2021-02-25 | Massachusetts Inst Technology | Collagen-localized immunomodulatory molecules and methods thereof |
EP3886866A1 (en) * | 2018-11-30 | 2021-10-06 | Mustang Bio, Inc. | Methods of treatment using decitabine and a cd123-targeted therapy |
AU2019402189B2 (en) | 2018-12-20 | 2023-04-13 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
BR112021015672A2 (pt) | 2019-02-15 | 2021-10-05 | Novartis Ag | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona substituída e usos dos mesmos |
BR112021015783A2 (pt) | 2019-02-15 | 2021-10-05 | Novartis Ag | Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina-2,6-diona e usos dos mesmos |
EP3931310A1 (en) | 2019-03-01 | 2022-01-05 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof |
US20220143087A1 (en) | 2019-03-08 | 2022-05-12 | Klinikum Der Universitat Munchen | Ccr8 expressing lymphocytes for targeted tumor therapy |
WO2020205751A1 (en) | 2019-03-29 | 2020-10-08 | City Of Hope | Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors |
WO2020219742A1 (en) | 2019-04-24 | 2020-10-29 | Novartis Ag | Compositions and methods for selective protein degradation |
WO2020263399A1 (en) | 2019-06-26 | 2020-12-30 | Massachusetts Institute Of Technology | Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof |
EP3769816A1 (en) * | 2019-07-25 | 2021-01-27 | Ospedale Pediatrico Bambino Gesù | Car-cd123 vector and uses thereof |
WO2021061648A1 (en) | 2019-09-23 | 2021-04-01 | Massachusetts Institute Of Technology | Methods and compositions for stimulation of endogenous t cell responses |
CN110904048A (zh) * | 2019-12-04 | 2020-03-24 | 合肥中科干细胞再生医学有限公司 | 一种car-cd123t2嵌合抗原受体t细胞及其应用 |
AU2020407065A1 (en) * | 2019-12-16 | 2022-06-23 | Washington University | Chimeric antigen receptor dendritic cells (CAR-DCs) and methods of making and using same |
KR20220116257A (ko) | 2019-12-20 | 2022-08-22 | 노파르티스 아게 | 골수섬유증 및 골수이형성 증후군을 치료하기 위한, 데시타빈 또는 항 pd-1 항체 스파르탈리주맙을 포함하거나 또는 포함하지 않는, 항 tim-3 항체 mbg453 및 항 tgf-베타 항체 nis793의 조합물 |
AU2021236145A1 (en) | 2020-03-10 | 2022-09-22 | Dana-Farber Cancer Institute, Inc. | Methods for generating engineered memory-like NK cells and compositions thereof |
CA3173981A1 (en) | 2020-03-10 | 2021-09-16 | Massachusetts Institute Of Technology | Compositions and methods for immunotherapy of npm1c-positive cancer |
CN113493772B (zh) * | 2020-04-08 | 2022-10-18 | 华中农业大学 | 可分泌性表达免疫毒素的嵌合抗原受体修饰的免疫细胞 |
US20210340524A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof |
US20210338833A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Chimeric antigen receptor-targeting ligands and uses thereof |
CA3185455A1 (en) | 2020-06-11 | 2021-12-16 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
CN115916199A (zh) | 2020-06-23 | 2023-04-04 | 诺华股份有限公司 | 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案 |
JP2023536164A (ja) | 2020-08-03 | 2023-08-23 | ノバルティス アーゲー | ヘテロアリール置換3-(1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその使用 |
CN112079927B (zh) * | 2020-09-18 | 2021-12-28 | 西安桑尼赛尔生物医药有限公司 | 一种cd123结合蛋白、含其的car及其应用 |
CN112521505B (zh) * | 2020-12-11 | 2022-07-29 | 华道(上海)生物医药有限公司 | 抗cd123抗体及其应用 |
CN112646033B (zh) * | 2020-12-16 | 2022-04-12 | 北京艺妙神州医药科技有限公司 | 靶向cd123的嵌合抗原受体及其用途 |
CN116635064A (zh) | 2020-12-18 | 2023-08-22 | 世纪治疗股份有限公司 | 具有适应性受体特异性的嵌合抗原受体系统 |
TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
WO2023021113A1 (en) | 2021-08-18 | 2023-02-23 | Julius-Maximilians-Universität Würzburg | Hybrid tumor/cancer therapy based on targeting the resolution of or inducing transcription-replication conflicts (trcs) |
WO2023081715A1 (en) | 2021-11-03 | 2023-05-11 | Viracta Therapeutics, Inc. | Combination of car t-cell therapy with btk inhibitors and methods of use thereof |
WO2023131657A1 (en) | 2022-01-05 | 2023-07-13 | Gyala Therapeutics Sociedad Limitada | Anti-cd84 antibodies and chimeric antigen receptors |
WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
WO2024094004A1 (zh) * | 2022-11-03 | 2024-05-10 | 重庆精准生物技术有限公司 | 靶向cd123的全人源抗体及其应用 |
WO2024098024A1 (en) | 2022-11-04 | 2024-05-10 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8414892B2 (en) | 2000-10-18 | 2013-04-09 | Sloan-Kettering Institute For Cancer Research | Uses of monoclonal antibody 8H9 |
US20020102264A1 (en) | 2000-10-18 | 2002-08-01 | Cheung Nai-Kong V. | Uses of monoclonal antibody 8H9 |
US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
EP1718310A4 (en) | 2004-02-06 | 2009-05-06 | Elan Pharm Inc | METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE |
US8163279B2 (en) | 2007-04-13 | 2012-04-24 | Stemline Therapeutics, Inc. | IL3Rα antibody conjugates and uses thereof |
JP5608100B2 (ja) | 2008-02-08 | 2014-10-15 | メディミューン,エルエルシー | 低下したFcリガンド親和性を有する抗IFNAR1抗体 |
ES2961498T3 (es) | 2008-08-26 | 2024-03-12 | Hope City | Método y composiciones para el funcionamiento mejorado del efecto antitumoral de las células T |
AU2010206681A1 (en) | 2009-01-23 | 2011-09-01 | Biogen Idec Ma Inc. | Stabilized Fc polypeptides with reduced effector function and methods of use |
JP5956342B2 (ja) | 2009-11-03 | 2016-07-27 | シティ・オブ・ホープCity of Hope | 形質導入T細胞選択のためのトランケート上皮増殖因子レセプタ(EGFRt) |
DK2614077T3 (en) | 2010-09-08 | 2016-11-21 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Chimeric antigen receptors with an optimized hinge region |
BR122021026169B1 (pt) | 2010-12-09 | 2023-12-12 | The Trustees Of The University Of Pennsylvania | Uso de uma célula |
EP3798230B1 (en) | 2011-06-06 | 2022-08-03 | Novo Nordisk A/S | Therapeutic antibodies |
EP2814846B1 (en) | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
WO2013126712A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer |
ES2814962T3 (es) | 2013-02-20 | 2021-03-29 | Novartis Ag | Fijación eficaz como objetivo de la leucemia humana primaria utilizando células T modificadas con receptor de antígeno quimérico anti-CD123 |
US9657105B2 (en) | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
TWI654206B (zh) | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗-cd19嵌合抗原受體治療癌症 |
JP6560235B2 (ja) | 2014-01-13 | 2019-08-14 | シティ・オブ・ホープCity of Hope | Fcスペーサー領域に変異を有するキメラ抗原受容体(CAR)及びそれらの使用方法 |
WO2016044811A1 (en) | 2014-09-19 | 2016-03-24 | City Of Hope | COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Rα2 |
-
2013
- 2013-03-15 US US13/844,048 patent/US9657105B2/en active Active
-
2014
- 2014-03-14 IL IL298332A patent/IL298332A/en unknown
- 2014-03-14 KR KR1020217027685A patent/KR102416258B1/ko active IP Right Grant
- 2014-03-14 IL IL289883A patent/IL289883B2/en unknown
- 2014-03-14 JP JP2016502984A patent/JP6588004B2/ja active Active
- 2014-03-14 KR KR1020157028939A patent/KR102297918B1/ko active IP Right Grant
- 2014-03-14 BR BR112015023701-0A patent/BR112015023701B1/pt active IP Right Grant
- 2014-03-14 MX MX2015013195A patent/MX2015013195A/es active IP Right Grant
- 2014-03-14 RU RU2015140624A patent/RU2711114C2/ru active
- 2014-03-14 EP EP19189084.7A patent/EP3626247B1/en active Active
- 2014-03-14 KR KR1020227022190A patent/KR102506668B1/ko active IP Right Grant
- 2014-03-14 CN CN201480024929.6A patent/CN105392887B/zh active Active
- 2014-03-14 KR KR1020237007335A patent/KR102556831B1/ko active IP Right Grant
- 2014-03-14 ES ES14765454T patent/ES2747099T3/es active Active
- 2014-03-14 NZ NZ712351A patent/NZ712351A/en unknown
- 2014-03-14 WO PCT/US2014/029109 patent/WO2014144622A2/en active Application Filing
- 2014-03-14 CA CA2907216A patent/CA2907216C/en active Active
- 2014-03-14 EP EP14765454.5A patent/EP2968415B1/en active Active
- 2014-03-14 DK DK14765454.5T patent/DK2968415T3/da active
- 2014-03-14 CN CN202010371579.8A patent/CN111926028A/zh not_active Withdrawn
- 2014-03-14 AU AU2014228911A patent/AU2014228911A1/en not_active Abandoned
-
2015
- 2015-09-15 MX MX2020001358A patent/MX2020001358A/es unknown
- 2015-09-16 IL IL241668A patent/IL241668B/en active IP Right Grant
-
2016
- 2016-09-09 HK HK16110734.2A patent/HK1222677A1/zh unknown
-
2017
- 2017-05-22 US US15/601,793 patent/US10660916B2/en active Active
-
2019
- 2019-04-05 AU AU2019202394A patent/AU2019202394A1/en not_active Abandoned
- 2019-09-12 JP JP2019166068A patent/JP6793800B2/ja active Active
-
2020
- 2020-04-27 US US16/859,590 patent/US11918606B2/en active Active
- 2020-11-10 JP JP2020187011A patent/JP7160882B2/ja active Active
-
2021
- 2021-03-16 IL IL281562A patent/IL281562B/en unknown
- 2021-04-30 AU AU2021202705A patent/AU2021202705A1/en active Pending
-
2022
- 2022-10-13 JP JP2022164487A patent/JP2022191388A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020001358A (es) | Celulas t que redirigen el receptor del antigeno quimerico especifico cd123 y metodos de su uso. | |
ZA201902047B (en) | Chimeric antigen receptors for the treatment of cancer | |
MA40253A (fr) | Cellules modifiées pour thérapie cellulaire adoptive | |
PH12019502424A1 (en) | Compositions and methods for immunotherapy | |
WO2019222275A3 (en) | Compositions and methods for tcr reprogramming using inducible fusion proteins | |
WO2018187613A3 (en) | Anti-icos agonist antibodies and uses thereof | |
MY190711A (en) | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor | |
MY181834A (en) | Treatment of cancer using humanized anti-bcma chimeric antigen receptor | |
PH12019502561A1 (en) | Novel monoclonal antibodies to cytotoxic t-lymphocyte-associated protein 4 (ctla-4) | |
WO2019147805A3 (en) | Regulatory t cells targeted with chimeric antigen receptors | |
AU2014236098A8 (en) | Treatment of cancer using humanized anti-CD19 chimeric antigen receptor | |
WO2017011804A8 (en) | Engineered cells for adoptive cell therapy | |
MX2017001013A (es) | Tratamiento de cáncer usando un receptor quimérico de antígeno cll-1. | |
MX2017001008A (es) | Tratamiento de cancer utilizando un receptor quimerico de antigeno cd33. | |
MY189028A (en) | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment | |
PH12015501493A1 (en) | Anti-pdgfr-beta antibodies and uses thereof | |
MX2016008076A (es) | Receptores quimericos de antigeno de mesotelina humana y uso de los mismos. | |
MY175869A (en) | Compositions and methods for immunotherapy | |
PH12020550242A1 (en) | Multifunctional immune cell therapies | |
MX2021002225A (es) | Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion. | |
EA201991854A1 (ru) | Агонистические антитела против icos и их применение |